This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProduction, part of CPhI Barcelona
8-10 October 2024

Kenneth Bilenberg
COO and Executive Vice President, Large Scale Business Unit at FUJIFILM Diosynth Biotechnologies


Kenneth Bilenberg, Chief Operating Officer & Executive Vice President, is member of the FUJIFILM Diosynth Biotechnologies Executive Leadership Team and is P&L responsible for the company’s Large Scale Biologics Business Unit. This Business Unit holds a leading position worldwide in terms of capacity and has a unique offering with the largest end to end clinical and commercial manufacturing production capacity across USA and Europe. As of 2025 capacity will be comprised of approximately 600,000 Liter Drug Substance Manufacturing Capacity, Drug Product capacity and finally Finished Goods capacity - all E2E at the same locations in USA and Europe. The area serves a high number of TOP20 Big Pharma companies as well as a number of Biotech companies, both startups and network based and enjoys high trust from clients. FUJIFILM Diosynth Biotechnologies has a strong People First culture and the Large Scale Biologics Business Unit will grow to more than 2,500 passionate people.

Kenneth has more than 20 years of experience as a proven leader, holding a variety of roles in the life science and biotechnology industries, specifically global pharmaceutical manufacturing companies, with involvement in three Greenfield Projects and as an executive leadership team member at manufacturing facilities worldwide. Kenneth’s career includes experience in all aspects of commercial- and operational excellence with key roles in manufacturing, finance, strategy/business planning, project management, supply chain management, procurement, facilities management and utilities, as well as IT and automation. Most recently, Kenneth has been leading the Greenbuild and Operational Readiness of the largest CDMO facility in North America.

Prior to joining FUJIFILM Diosynth Biotechnologies in 2019, Kenneth served as a member of the Executive Leadership Teams at Novo Nordisk’s manufacturing sites in Tianjin, China; Clayton, North Carolina (USA) and Hillerod, Denmark as well as in Senior Leadership teams across Staff functions in a head quarter setting.

Agenda Sessions

  • Creating the largest E2E CDMO network to change the future of Biologics Market Supply